Galecto Biotech Report issue

For profit Phase 1 Phase 2
Founded: Copenhagen Denmark (2011)
Status: Acquired by Bristol-Myers Squibb (2014)

Organization Overview

First Clinical Trial
2014
NCT02257177
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Galecto Biotech AB

Active Ingredients

Drugs in Phase 2 Trials (5)

atezolizumab (Tecentriq) (1 trial)

gb1211 (6 trials)

gb2064 (1 trial)

pembrolizumab (keytruda) (1 trial)

td139 (2 trials)

Drugs in Phase 1 Trials (1)

Key: Galecto Biotech (0) Acquired (1)

pat-1251 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fatty Liver (Phase 2)

Fibrosis (Phase 2)

Idiopathic Pulmonary Fibrosis (Phase 2)

Liver Cirrhosis (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Primary Myelofibrosis (Phase 2)

Pulmonary Fibrosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 6